The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | The importance of proteomics in myeloma and how this may be implemented in clinical practice
Arun Wiita, MD, PhD, University of California, San Francisco, CA, discusses how characterizing the myeloma cell surface proteome for different patient populations can lead to the identification of novel immunotherapeutic targets and markers of resistance in myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Roche/Genentech
